Unmet needs in the management of atherosclerotic cardiovascular disease: Is there a role for emerging anti-inflammatory interventions?
详细信息 查看全文
- 作者：Alberto J. Lorenzattia ; b ; alorenzatti@powernet.net.ar" class="auth_mail" title="E-mail the corresponding author ; Brenda M. Retzlaffc
- 关键词：ACS ; acute coronary syndrome ; ASCVD ; Atherosclerotic Cardiovascular Disease ; AFCAPS/TexCAPS ; Air Force/Texas Coronary Atherosclerosis Prevention primary prevention ; CAD ; coronary artery disease ; CANTOS ; Canakinumab Anti-inflammatory Thrombosis Outcomes Study ; CARE ; Cholesterol and Recurrent Events ; CI ; confidence interval ; CIRT ; Cardiovascular Inflammation Reduction Trial ; CRP ; C-reactive protein ; CV ; cardiovascular ; hs-CRP ; high- sensitivity CRP ; IFN-γ ; interferon gamma ; IL ; interleukin ; IL-1Ra
- 刊名：International Journal of Cardiology
- 出版年：2016
- 出版时间：15 October 2016
- 年：2016
- 卷：221
- 期：Complete
- 页码：581-586
- 全文大小：382 K
文摘
- •
Atherosclerotic cardiovascular disease is the leading cause of death worldwide.
- •
Despite effective medications, there still remains a significant residual CV risk.
- •
This review discusses the role of inflammation and interleukin-1β in atherogenesis.
- •
Targeting anti-IL-1 therapy provides important future benefits in ASCVD treatment.
- •
Two large-scale clinical trials, CIRT and CANTOS based on this approach are ongoing.